Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
32.84 (1y: +98%)
Market Cap 4.39 B P/E(ttm)
Enterprise Value 4.55 B P/B 5.12
ALKS- NAS (USA)
Alkermes PLC
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$32.84
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.428
ALKS's Cash to Debt is ranked lower than
88% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. ALKS: 0.428 )
ALKS' s 10-Year Cash to Debt Range
Min: 0.43   Max: No Debt
Current: 0.43
Equity to Asset 0.1
ALKS's Equity to Asset is ranked lower than
84% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. ALKS: 0.1 )
ALKS' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.87
Current: 0.1
-0.02
0.87
F-Score: 4
Z-Score: 5.31
M-Score: -3.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry		 vs
history
Operating margin (%) -22.60
ALKS's Operating margin (%) is ranked higher than
53% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. ALKS: -22.60 )
ALKS' s 10-Year Operating margin (%) Range
Min: -331.3   Max: 41.3
Current: -22.6
-331.3
41.3
Net-margin (%) -29.1
ALKS's Net-margin (%) is ranked higher than
50% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. ALKS: -29.1 )
ALKS' s 10-Year Net-margin (%) Range
Min: -296.9   Max: 69.4
Current: -29.1
-296.9
69.4
ROE (%) -13.3
ALKS's ROE (%) is ranked lower than
55% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. ALKS: -13.3 )
ALKS' s 10-Year ROE (%) Range
Min: -1797.6   Max: 54.7
Current: -13.3
-1797.6
54.7
ROA (%) -7.9
ALKS's ROA (%) is ranked higher than
52% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. ALKS: -7.9 )
ALKS' s 10-Year ROA (%) Range
Min: -41.8   Max: 25.4
Current: -7.9
-41.8
25.4
ROC (Joel Greenblatt) (%) -24.10
ALKS's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALKS: -24.10 )
ALKS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -310.2   Max: 116.8
Current: -24.1
-310.2
116.8
EBITDA Growth (%) -57.3
ALKS's EBITDA Growth (%) is ranked lower than
98% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALKS: -57.3 )
ALKS' s 10-Year EBITDA Growth (%) Range
Min: -57.3   Max: 56.8
Current: -57.3
-57.3
56.8
ยป ALKS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ALKS Guru Trades in Q2 2012

Jim Simons 389,086 sh (New)
Paul Tudor Jones 38,100 sh (+78.04%)
Vanguard Health Care Fund 837,400 sh (+6.28%)
Murray Stahl 25,000 sh (unchged)
Bruce Kovner Sold Out
Jeff Auxier 60,676 sh (-0.53%)
Pioneer Investments 786,267 sh (-9.7%)
Steven Cohen 12,387 sh (-82.42%)
» More
Q3 2012

ALKS Guru Trades in Q3 2012

Steven Cohen 156,921 sh (+1166.82%)
Vanguard Health Care Fund 837,400 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Pioneer Investments 759,717 sh (-3.38%)
Jeff Auxier 54,901 sh (-9.52%)
Jim Simons 142,386 sh (-63.41%)
Paul Tudor Jones 13,200 sh (-65.35%)
» More
Q4 2012

ALKS Guru Trades in Q4 2012

Steven Cohen 180,586 sh (+15.08%)
Vanguard Health Care Fund 837,400 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 54,151 sh (-1.37%)
Paul Tudor Jones 12,600 sh (-4.55%)
Pioneer Investments 631,549 sh (-16.87%)
Jim Simons 44,786 sh (-68.55%)
» More
Q1 2013

ALKS Guru Trades in Q1 2013

Jim Simons 117,800 sh (+163.03%)
Vanguard Health Care Fund 1,233,024 sh (+47.24%)
Jeff Auxier 54,551 sh (+0.74%)
Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones 11,900 sh (-5.56%)
Pioneer Investments 511,849 sh (-18.95%)
Steven Cohen 13,214 sh (-92.68%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-03-31 Add 47.24%0.04%$18.52 - $23.81 $ 32.8450%1233024
John Burbank 2012-03-31 Sold Out 0.23%$16.14 - $19.5 $ 32.8499%0
Vanguard Health Care Fund 2012-03-31 New Buy0.07%$16.14 - $19.5 $ 32.8499%787900
Daniel Loeb 2010-06-30 Sold Out 0.92%$10.7 - $13.75 $ 32.84166%0
Daniel Loeb 2010-03-31 New Buy0.92%$9.41 - $14.01 $ 32.84183%1000000
Jean-Marie Eveillard 2010-03-31 Sold Out 0.01%$9.41 - $14.01 $ 32.84183%0
George Soros 2010-03-31 Sold Out $9.41 - $14.01 $ 32.84183%0
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 5.12
ALKS's P/B is ranked lower than
62% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ALKS: 5.12 )
ALKS' s 10-Year P/B Range
Min: 1.56   Max: 474.75
Current: 5.12
1.56
474.75
P/S 8.07
ALKS's P/S is ranked lower than
51% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. ALKS: 8.07 )
ALKS' s 10-Year P/S Range
Min: 2.19   Max: 202.17
Current: 8.07
2.19
202.17
PFCF 65.68
ALKS's PFCF is ranked lower than
71% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 30.73 vs. ALKS: 65.68 )
ALKS' s 10-Year PFCF Range
Min: 10.27   Max: 153.33
Current: 65.68
10.27
153.33
EV-to-EBIT 882.45
ALKS's EV-to-EBIT is ranked lower than
99% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. ALKS: 882.45 )
ALKS' s 10-Year EV-to-EBIT Range
Min: 3.6   Max: 905.9
Current: 882.45
3.6
905.9
Shiller P/E 128.35
ALKS's Shiller P/E is ranked lower than
100% of the Companies
in the Global Biotechnology industry.

( Industry Median: vs. ALKS: 128.35 )
ALKS' s 10-Year Shiller P/E Range
Min: 27.92   Max: 296
Current: 128.35
27.92
296

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 49.5
ALKS's Price/Net Current Asset Value is ranked lower than
57% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. ALKS: 49.5 )
ALKS' s 10-Year Price/Net Current Asset Value Range
Min: 24.1   Max: 1156.3
Current: 49.5
24.1
1156.3
Price/Tangible Book 30.4
ALKS's Price/Tangible Book is ranked lower than
93% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. ALKS: 30.4 )
ALKS' s 10-Year Price/Tangible Book Range
Min: 2.7   Max: 207.6
Current: 30.4
2.7
207.6
Price/DCF (Projected) 6.8
ALKS's Price/DCF (Projected) is ranked lower than
83% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. ALKS: 6.8 )
ALKS' s 10-Year Price/DCF (Projected) Range
Min: 2.3   Max: 3.9
Current: 6.8
2.3
3.9
Price/Median PS Value 1.4
ALKS's Price/Median PS Value is ranked higher than
52% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALKS: 1.4 )
ALKS' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 12.3
Current: 1.4
0.4
12.3
Earnings Yield (Greenblatt) 0.10
ALKS's Earnings Yield (Greenblatt) is ranked lower than
57% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. ALKS: 0.10 )
ALKS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 27.9
Current: 0.1
0.1
27.9
Forward Rate of Return (Yacktman) -0.07
ALKS's Forward Rate of Return (Yacktman) is ranked lower than
59% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALKS: -0.07 )
ALKS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.1   Max: 2.3
Current: -0.07
-6.1
2.3

Business Description

Alkermes PLC was incorporated in Ireland in 2011. It is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. It developed, manufacture and commercialize VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar disorder. The company's pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. RISPERDAL CONSTA is a long-acting formulation of risperidone, a product of Janssen Pharmaceutica, Inc., a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica International, a division of Cilag International (together 'Janssen'), and is the first and only long-acting, atypical antipsychotic approved by the United States (U.S.) Food and Drug Administration (FDA). VIVITROL is an extended-release Medisorb formulation of naltrexone developed by Alkermes. VIVITROL is the first and only once-monthly injectable medication for the treatment of alcohol dependence. VIVITROL is sold directly to pharmaceutical wholesalers, specialty pharmacies and a specialty distributor. The biotechnology and pharmaceutical industries are subject to rapid and substantial technological change.
Company Website
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:8AK.Germany
ยป More Articles for NAS:ALKS

Headlines

Articles On GuruFocus.com
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 09 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 
Weekly Guru Bargains Highlights: Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Dec 12 2009 
Alkermes Inc. Reports Operating Results (10-Q) Nov 05 2009 

More From Our Partners
Biogen Submits Plegridy BLA - Analyst Blog May 23 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial